Fig. 5

The response of engineered T47D cells expressing ectopic ESR1–CCDC170 fusion to HER2 or SRC inhibitors in combination with tamoxifen. a The responses of the T47D cells expressing a control vector, ESR1–CCDC170 variants, or wtCCDC170 to tamoxifen (0.5 μM), lapatinib (0.5 μM), or their combination as measured by clonogenic assays. The cells were cultured under phenol red-free medium and treated with the indicated drugs for 15 days before fixation and staining. Upper panel, the representative images of clonogenic assays. Lower panel, the relative intensities normalized to the vector control cells treated with vehicle (means ± SD of triplicates). b Responses of the engineered T47D cells to 4-OH tamoxifen (0.5 μM), SRC inhibitor dasatinib (0.05 μM), or their combination as measured by clonogenic assay. The cells were cultured and treated in a similar way as in a. Upper panel, the representative images of clonogenic assays. Lower panel, the relative intensities normalized to the vector control treated with vehicle (means ± SD of triplicates)